Julia A Newton-Bishop

List of Publications by Citations

175 papers	8,609 citations	50 h-index	87 g-index
202 ext. papers	9,994 ext. citations	8.3 avg, IF	5.06 L-index

#	Paper	IF	Citations
175	Genome-wide association study identifies three loci associated with melanoma risk. *Nature Genetics*, **2009**, 41, 920-5	36.3	360
174	Excision margins in high-risk malignant melanoma. *New England Journal of Medicine*, **2004**, 350, 757-66	59.2	341
173	A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. *Nature*, **2011**, 480, 99-103	50.4	335
172	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. *European Journal of Cancer*, **2016**, 63, 201-17	7.5	265
171	POT1 loss-of-function variants predispose to familial melanoma. *Nature Genetics*, **2014**, 46, 478-481	36.3	241
170	Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. *European Journal of Cancer*, **2010**, 46, 270-83	7.5	230
169	Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. *Journal of Clinical Oncology*, **2009**, 27, 5439-44	2.2	212
168	Genome-wide association study identifies three new melanoma susceptibility loci. *Nature Genetics*, **2011**, 43, 1108-13	36.3	203
167	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. *European Journal of Cancer*, **2012**, 48, 2375-90	7.5	199
166	A road map for efficient and reliable human genome epidemiology. *Nature Genetics*, **2006**, 38, 3-5	36.3	198
165	Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. *International Journal of Epidemiology*, **2009**, 38, 814-30	7.8	187
164	Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. *Nature Genetics*, **2009**, 41, 915-9	36.3	186
163	Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. *Journal of Clinical Oncology*, **1999**, 17, 3245-51	2.2	185
162	Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. *Journal of Clinical Oncology*, **2011**, 29, 2206-14	2.2	164
161	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. *Nature Genetics*, **2015**, 47, 987-995	36.3	162
160	Effect of pregnancy on survival in women with cutaneous malignant melanoma. *Journal of Clinical Oncology*, **2004**, 22, 4369-75	2.2	130
159	Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. *Nature Genetics*, **2011**, 43, 1114-8	36.3	126

158	Selection criteria for genetic assessment of patients with familial melanoma. *Journal of the American Academy of Dermatology*, **2009**, 61, 677.e1-14	4.5	115
157	Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. *European Journal of Cancer*, **2009**, 45, 3271-81	7.5	108
156	Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts. *Molecular and Cellular Biology*, **2002**, 22, 8135-43	4.8	108
155	Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	102
154	IRF4 variants have age-specific effects on nevus count and predispose to melanoma. *American Journal of Human Genetics*, **2010**, 87, 6-16	11	100
153	The effect on melanoma risk of genes previously associated with telomere length. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	97
152	Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. *Journal of the National Cancer Institute*, **2018**, 110, 1328-1341	9.7	97
151	A variant in FTO shows association with melanoma risk not due to BMI. *Nature Genetics*, **2013**, 45, 428-32, 432e1	36.3	95
150	The emergence of networks in human genome epidemiology: challenges and opportunities. *Epidemiology*, **2007**, 18, 1-8	3.1	93
149	A network of investigator networks in human genome epidemiology. *American Journal of Epidemiology*, **2005**, 162, 302-4	3.8	92
148	Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. *Journal of Investigative Dermatology*, **2001**, 117, 348-52	4.3	92
147	Predictors of sun protection behaviors and severe sunburn in an international online study. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2199-210	4	91
146	Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. *Modern Pathology*, **2012**, 25, 493-504	9.8	91
145	Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. *International Journal of Cancer*, **1996**, 67, 485-91	7.5	90
144	Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. *Journal of Medical Genetics*, **2013**, 50, 264-70	5.8	89
143	Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2043-54	4	83
142	Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. *Clinical Cancer Research*, **2009**, 15, 6939-46	12.9	83
141	Frequent p16-independent inactivation of p14ARF in human melanoma. *Journal of the National Cancer Institute*, **2008**, 100, 784-95	9.7	83

140	Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. *Journal of Investigative Dermatology*, **2000**, 114, 28-33	4.3	83
139	Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. *Lancet Oncology, The*, **2016**, 17, 184-192	21.7	82
138	Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case-control study in a temperate climate. *European Journal of Cancer*, **2011**, 47, 732-41	7.5	80
137	Surgical excision methods for skin cancer involving the nail unit. *The Cochrane Library*,	5.2	78
136	A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. *International Journal of Cancer*, **2009**, 124, 420-8	7.5	72
135	MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. *International Journal of Cancer*, **2015**, 136, 618-31	7.5	67
134	A mutation hotspot at the p14ARF splice site. *Oncogene*, **2005**, 24, 4604-8	9.2	67
133	Genetic heterogeneity in familial malignant melanoma. *Human Molecular Genetics*, **1994**, 3, 2195-200	5.6	63
132	UK guidelines for the management of cutaneous melanoma. *Journal of Plastic, Reconstructive and Aesthetic Surgery*, **2002**, 55, 46-54		60
131	Risk of ocular melanoma in relation to cutaneous and iris naevi. *International Journal of Cancer*, **1995**, 60, 622-6	7.5	55
130	The effect of sun exposure in determining nevus density in UK adolescent twins. *Journal of Investigative Dermatology*, **2005**, 124, 56-62	4.3	53
129	Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. *Archives of Surgery*, **2002**, 137, 1101-5		52
128	Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. *Pigment Cell and Melanoma Research*, **2012**, 25, 384-94	4.5	50
127	Melanoma and vitamin D. *Molecular Oncology*, **2011**, 5, 197-214	7.9	50
126	Spontaneous involution of congenital melanocytic nevi of the scalp. *Journal of the American Academy of Dermatology*, **2008**, 58, 508-11	4.5	50
125	Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. *Human Mutation*, **1998**, 11, 424-31	4.7	49
124	Mutation testing in melanoma families: INK4A, CDK4 and INK4D. *British Journal of Cancer*, **1999**, 80, 295-300	8.7	49
123	Patterns of expression of DNA repair genes and relapse from melanoma. *Clinical Cancer Research*, **2010**, 16, 5211-21	12.9	48

122	Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways. *Nature Communications*, **2018**, 9, 4774	17.4	47
121	Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. *Journal of Clinical Investigation*, **2018**, 128, 2048-2063	15.9	46
120	Melanoma sentinel node biopsy and prediction models for relapse and overall survival. *British Journal of Cancer*, **2010**, 103, 1229-36	8.7	43
119	25-Hydroxyvitamin D2 /D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort. *International Journal of Cancer*, **2015**, 136, 2890-9	7.5	42
118	Melanoma risk factors, perceived threat and intentional tanning: an international online survey. *European Journal of Cancer Prevention*, **2010**, 19, 216-26	2	41
117	Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. *Genes Chromosomes and Cancer*, **2010**, 49, 425-38	5	40
116	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. *Nature Genetics*, **2020**, 52, 494-504	36.3	39
115	MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. *International Journal of Cancer*, **2015**, 136, 2844-53	7.5	39
114	Identification of a melanoma susceptibility locus and somatic mutation in TET2. *Carcinogenesis*, **2014**, 35, 2097-101	4.6	38
113	Trends in prognostic factors and survival from cutaneous melanoma in Yorkshire, UK and New South Wales, Australia between 1993 and 2003. *International Journal of Cancer*, **2008**, 123, 861-6	7.5	37
112	Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. *Oncotarget*, **2014**, 5, 3273-86	3.3	37
111	Assessing the Incremental Contribution of Common Genomic Variants to Melanoma Risk Prediction in Two Population-Based Studies. *Journal of Investigative Dermatology*, **2018**, 138, 2617-2624	4.3	36
110	A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF. *Nature Genetics*, **2017**, 49, 1326-1335	36.3	36
109	A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. *Journal of Investigative Dermatology Symposium Proceedings*, **2004**, 9, 152-9	1.1	35
108	Prevalence of 9p21 deletions in UK melanoma families. *Genes Chromosomes and Cancer*, **2005**, 44, 292-300	3	35
107	The atypical-mole syndrome and predisposition to melanoma. *New England Journal of Medicine*, **1998**, 339, 348-9	59.2	35
106	Germline TERT promoter mutations are rare in familial melanoma. *Familial Cancer*, **2016**, 15, 139-44	3	34
105	Overseas sun exposure, nevus counts, and premature skin aging in young English women: a population-based survey. *Journal of Investigative Dermatology*, **2009**, 129, 50-9	4.3	34

104	The relationship between the epidermal growth factor (EGF) 5′UTR variant A61G and melanoma/nevus susceptibility. *Journal of Investigative Dermatology*, **2004**, 123, 755-9	4.3	34
103	Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. *Oncotarget*, **2015**, 6, 11683-93	3.3	34
102	variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project. *Cancer Management and Research*, **2018**, 10, 1143-1154	3.6	32
101	CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. *Melanoma Research*, **2007**, 17, 185-91	3.3	32
100	Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. *Cancer Research*, **2019**, 79, 2684-2696	10.1	31
99	Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. *Hereditary Cancer in Clinical Practice*, **2014**, 12, 20	2.3	31
98	Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK. *Journal of Medical Genetics*, **2011**, 48, 266-72	5.8	30
97	The genetics of susceptibility to cutaneous melanoma. *Drugs of Today*, **2005**, 41, 193-203		30
96	An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. *Journal of Investigative Dermatology*, **2002**, 119, 961-5	4.3	29
95	Intronic sequence variants of the CDKN2A gene in melanoma pedigrees. *Genes Chromosomes and Cancer*, **2005**, 43, 128-36	5	29
94	Loss-of-Function Mutations in the Cell-Cycle Control Gene CDKN2A Impact on Glucose Homeostasis in Humans. *Diabetes*, **2016**, 65, 527-33	0.9	28
93	Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination. *Archives of Dermatology*, **2012**, 148, 1142-51		28
92	High nevus counts confer a favorable prognosis in melanoma patients. *International Journal of Cancer*, **2015**, 137, 1691-8	7.5	27
91	The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate. *Cancer Causes and Control*, **2011**, 22, 1471-82	2.8	27
90	Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. *Nature Communications*, **2017**, 8, 15034	17.4	26
89	Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. *International Journal of Cancer*, **2015**, 136, 1351-60	7.5	26
88	Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. *Journal of Clinical Oncology*, **2020**, 38, 1591-1601	2.2	26
87	A population-based analysis of germline BAP1 mutations in melanoma. *Human Molecular Genetics*, **2017**, 26, 717-728	5.6	24

86	MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study. *BMC Cancer*, **2013**, 13, 406	4.8	24
85	The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. *Pigment Cell and Melanoma Research*, **2015**, 28, 94-104	4.5	23
84	Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. *Journal of Clinical Oncology*, **2013**, 31, e320-1	2.2	23
83	Molecular pathology of melanoma. *Cancer and Metastasis Reviews*, **1997**, 16, 141-54	9.6	23
82	No Evidence for BRAF as a melanoma/nevus susceptibility gene. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 913-8	4	23
81	Vitamin D-VDR Signaling Inhibits Wnt/Catenin-Mediated Melanoma Progression and Promotes Antitumor Immunity. *Cancer Research*, **2019**, 79, 5986-5998	10.1	23
80	Identification of a gene signature for discriminating metastatic from primary melanoma using a molecular interaction network approach. *Scientific Reports*, **2017**, 7, 17314	4.9	22
79	Inherited variation in the PARP1 gene and survival from melanoma. *International Journal of Cancer*, **2014**, 135, 1625-33	7.5	22
78	An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study. *Pigment Cell and Melanoma Research*, **2014**, 27, 234-43	4.5	21
77	Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia. *Journal of the American Academy of Dermatology*, **2011**, 65, 676-677	4.5	21
76	An assessment of a variant of the DNA repair gene XRCC3 as a possible nevus or melanoma susceptibility genotype. *Journal of Investigative Dermatology*, **2004**, 122, 429-32	4.3	21
75	Vitamin D and melanoma. *Dermato-Endocrinology*, **2013**, 5, 121-9		20
74	Genetics: what advice for patients who present with a family history of melanoma?. *Seminars in Oncology*, **2007**, 34, 452-9	5.5	20
73	Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities. *Journal of Investigative Dermatology*, **2016**, 136, 2502-2505	4.3	18
72	Development and validation of a melanoma risk score based on pooled data from 16 case-control studies. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 817-24	4	18
71	Cutaneous melanoma during pregnancy: is the controversy over?. *Journal of Clinical Oncology*, **2009** , 27, e11-2; author reply e13-4	2.2	17
70	Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis. *Cancer Discovery*, **2020**, 10, 980-997	24.4	17
69	Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	16

68	Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma. *Clinical Cancer Research*, **2019**, 25, 7424-7435	12.9	16
67	Melanoma: summary of NICE guidance. *BMJ, The*, **2015**, 351, h3708	5.9	16
66	Histologic features of melanoma associated with CDKN2A genotype. *Journal of the American Academy of Dermatology*, **2015**, 72, 496-507.e7	4.5	16
65	Pathway-based analysis of a melanoma genome-wide association study: analysis of genes related to tumour-immunosuppression. *PLoS ONE*, **2011**, 6, e29451	3.7	16
64	Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study. *Journal of Investigative Dermatology*, **2014**, 134, 287-290	4.3	15
63	Malignant melanoma in pregnancy. *Obstetrics and Gynecology Clinics of North America*, **2005**, 32, 559-68	3.3	15
62	Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma. *JAMA Dermatology*, **2019**, 155, 604-609	5.1	15
61	Germline /P16INK4A mutations contribute to genetic determinism of sarcoma. *Journal of Medical Genetics*, **2017**, 54, 607-612	5.8	14
60	Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma. *European Journal of Cancer*, **2012**, 48, 3052-62	7.5	14
59	Clinicopathologic features of V600E and V600K melanoma--letter. *Clinical Cancer Research*, **2012**, 18, 6792; author reply p. 6793	12.9	14
58	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.. *Nature Medicine*, **2022**,	50.5	14
57	The determinants of periorbital skin ageing in participants of a melanoma case-control study in the U.K. *British Journal of Dermatology*, **2011**, 165, 1011-21	4	13
56	Environmental risk factors for relapse of melanoma. *European Journal of Cancer*, **2008**, 44, 1717-25	7.5	13
55	Sun-protective behaviors in families at increased risk of melanoma. *Journal of Investigative Dermatology*, **2007**, 127, 1343-50	4.3	13
54	Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: A Pooled Analysis from the M-Skip Project. *Journal of Investigative Dermatology*, **2016**, 136, 1914-1917	4.3	12
53	Relationship between sunbed use and melanoma risk in a large case-control study in the United Kingdom. *International Journal of Cancer*, **2012**, 130, 3011-3	7.5	12
52	Comparative genomics reveals that loss of lunatic fringe (LFNG) promotes melanoma metastasis. *Molecular Oncology*, **2018**, 12, 239-255	7.9	12
51	Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma. *Journal of Investigative Dermatology*, **2015**, 135, 2328-2331	4.3	10

50	Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families. *Journal of Investigative Dermatology*, **2017**, 137, 2606-2612	4.3	10
49	Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies. *BMC Medical Research Methodology*, **2012**, 12, 116	4.7	10
48	Management of regional lymph nodes in patients with malignant melanoma: questionnaire survey of UK current practice. *Journal of Plastic, Reconstructive and Aesthetic Surgery*, **2002**, 55, 372-5		10
47	Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. *JCO Precision Oncology*, **2020**, 3,	3.6	10
46	Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. *Journal of Investigative Dermatology*, **2016**, 136, 1066-1069	4.3	9
45	Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. *Journal of the American Academy of Dermatology*, **2019**, 81, 386-394	4.5	9
44	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. *The Lancet Child and Adolescent Health*, **2019**, 3, 332-342	14.5	8
43	The CDKN2A/p16(INK) (4a) 5RUTR sequence and translational regulation: impact of novel variants predisposing to melanoma. *Pigment Cell and Melanoma Research*, **2016**, 29, 210-21	4.5	8
42	25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. *British Journal of Cancer*, **2018**, 119, 793-800	8.7	8
41	Histopathology of melanocytic lesions in a family with an inherited BAP1 mutation. *Journal of Cutaneous Pathology*, **2016**, 43, 287-9	1.7	8
40	Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts. *Cancers*, **2020**, 12,	6.6	7
39	Environmental Exposures Such as Smoking and Low Vitamin D Are Predictive of Poor Outcome in Cutaneous Melanoma rather than Other Deprivation Measures. *Journal of Investigative Dermatology*, **2020**, 140, 327-337.e2	4.3	7
38	Do vitamin A serum levels moderate outcome or the protective effect of vitamin D on outcome from malignant melanoma?. *Clinical Nutrition*, **2013**, 32, 1012-6	5.9	6
37	Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk. *Carcinogenesis*, **2013**, 34, 885-92	4.6	6
36	Laryngo-onycho-cutaneous syndrome. *Ophthalmology*, **2010**, 117, 1056-1056.e2	7.3	6
35	MX 2 is a novel regulator of cell cycle in melanoma cells. *Pigment Cell and Melanoma Research*, **2020** , 33, 446-457	4.5	6
34	Psychosocial, clinical and demographic features related to worry in patients with melanoma. *Melanoma Research*, **2016**, 26, 497-504	3.3	6
33	Vitamin D, vitamin A, the primary melanoma transcriptome and survival. *British Journal of Dermatology*, **2016**, 175 Suppl 2, 30-34	4	6

32	Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study. *Journal of the National Cancer Institute*, **2021**, 113, 318-328	9.7	6
31	Regressing Eruptive Disseminated Spitz Nevi. *Pediatric Dermatology*, **2015**, 32, e181-3	1.9	5
30	Amelanotic melanoma. *BMJ, The*, **2018**, 360, k826	5.9	5
29	Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass. *Journal of Investigative Dermatology*, **2014**, 134, 3000-3003	4.3	5
28	Identification of differentially expressed genes in matched formalin-fixed paraffin-embedded primary and metastatic melanoma tumor pairs. *Pigment Cell and Melanoma Research*, **2012**, 25, 284-6	4.5	5
27	Evaluation of PAX3 genetic variants and nevus number. *Pigment Cell and Melanoma Research*, **2013**, 26, 666-76	4.5	5
26	Genomic expression differences between cutaneous cells from red hair color individuals and black hair color individuals based on bioinformatic analysis. *Oncotarget*, **2017**, 8, 11589-11599	3.3	5
25	Tumour gene expression signature in primary melanoma predicts long-term outcomes. *Nature Communications*, **2021**, 12, 1137	17.4	5
24	High-Resolution Copy Number Patterns From Clinically Relevant FFPE Material. *Scientific Reports*, **2019**, 9, 8908	4.9	4
23	Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study. *BMC Cancer*, **2017**, 17, 5	4.8	4
22	Association between putative functional variants in the PSMB9 gene and risk of melanoma--re-analysis of published melanoma genome-wide association studies. *Pigment Cell and Melanoma Research*, **2013**, 26, 392-401	4.5	4
21	Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. *Developmental Cell*, **2021**, 56, 2808-2825.e10	10.2	4
20	ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation. *Journal of Biomedical Science*, **2021**, 28, 76	13.3	3
19	Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). *Cancer*, **2004**, 100, 433-4; author reply 434	6.4	2
18	Tumour gene expression signature in primary melanoma predicts long-term outcomes: A prospective multicentre study		2
17	Cell state diversity promotes metastasis through heterotypic cluster formation in melanoma		2
16	Gene co-expression and histone modification signatures are associated with melanoma progression, epithelial-to-mesenchymal transition, and metastasis. *Clinical Epigenetics*, **2020**, 12, 127	7.7	2
15	MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project. *Melanoma Research*, **2020**, 30, 500-510	3.3	2

14	Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families. *BMC Public Health*, **2021**, 21, 692	4.1	2
13	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. *ESMO Open*, **2018**, 3, e000408	6	2
12	Tests to assist in the staging of cutaneous melanoma: a generic protocol. *The Cochrane Library*, **2017**,	5.2	1
11	Response to P. Autier and M. Boniol regarding our article--Relationship between sunbed use and melanoma risk in a large case-control study in the United Kingdom. *International Journal of Cancer*, **2013**, 132, 1960-1	7.5	1
10	Melanocytic Naevi and Melanoma **2011**, 109.1-109.28		1
9	Melanoma. *British Journal of Hospital Medicine*, **2000**, 61, 103-7		1
8	MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy. *Cancer Medicine*, **2021**, 10, 2840-2854	4.8	0
7	Transcriptional signatures underlying dynamic phenotypic switching and novel disease biomarkers in a linear cellular model of melanoma progression. *Neoplasia*, **2021**, 23, 439-455	6.4	0
6	Inherited duplications of PPP2R3B predispose to nevi and melanoma via a C21orf91-driven proliferative phenotype. *Genetics in Medicine*, **2021**, 23, 1636-1647	8.1	0
5	AuthorsRreply to: High naevus counts confer a favourable prognosis in patients with melanoma. *International Journal of Cancer*, **2015**, 137, 3008-9	7.5	
4	EORTC Melanoma Group achievements. *European Journal of Cancer, Supplement*, **2012**, 10, 112-119	1.6	
3	Reply to P.E. Hutchinson et al. *Journal of Clinical Oncology*, **2010**, 28, e494-e495	2.2	
2	ctDNA as a noninvasive monitoring tool in metastatic melanoma.. *Journal of Clinical Oncology*, **2019** , 37, 9548-9548	2.2	
1	Melanoma and reproductive health257-264		